Cipla Stock Screener | Share Price & Fundamental Analysis
CIPLA
Pharmaceuticals
Screen Cipla share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1530.80
▲
11.00 (0.72%)
Share Price BSE
₹1530.35
▲
11.05 (0.73%)
Market Cap
₹121,238.47 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.71
EPS (TTM)
₹65.29
Dividend Yield
1.06%
Debt to Equity
0.02
52W High
₹1645.10
52W Low
₹1384.70
Operating Margin
24.00%
Profit Margin
17.53%
Revenue (TTM)
₹7,716.00
EBITDA
₹2,022.00
Net Income
₹1,353.00
Total Assets
₹37,387.00
Total Equity
₹31,289.00
Cipla Share Price History - Stock Screener Chart
Screen CIPLA historical share price movements with interactive charts. Analyze price trends and patterns.
Cipla Company Profile - Fundamental Screener
Screen Cipla company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CIPLA shares.
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Y K Hamied
ISIN
INE059A01026
Website
https://www.cipla.com
Cipla Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen CIPLA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 | 21,128 |
| Current Assets | 23,249 | 19,392 | 16,805 | 14,711 | 13,210 | 11,706 | 12,427 | 10,814 | 8,736 | 8,841 |
| Fixed Assets | 10,006 | 9,607 | 9,161 | 9,683 | 9,516 | 9,683 | 9,608 | 9,950 | 9,492 | 9,369 |
| Liabilities | ||||||||||
| Total Liabilities | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 | 21,128 |
| Current Liabilities | 614 | 670 | 640 | 1,071 | 1,975 | 3,212 | 4,848 | 4,447 | 4,682 | 1,486 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 31,289 | 26,802 | 23,714 | 21,117 | 18,586 | 16,057 | 15,344 | 14,582 | 12,982 | 11,866 |
| Share Capital | 162 | 162 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 |
| Reserves & Surplus | 31,032 | 26,545 | 23,246 | 20,680 | 18,165 | 15,602 | 14,851 | 14,068 | 12,383 | 11,356 |
Screen CIPLA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,716 | 7,096 | 6,887 | 7,183 | 7,152 | 6,785 | 6,332 | 6,690 | 6,766 | 6,406 | 5,801 | 5,845 | 5,882 | 5,421 | 5,288 |
| Expenses | 5,695 | 5,179 | 5,192 | 5,084 | 5,165 | 4,978 | 4,847 | 5,051 | 4,944 | 4,835 | 4,748 | 4,403 | 4,526 | 4,232 | 4,568 |
| EBITDA | 2,022 | 1,916 | 1,695 | 2,099 | 1,986 | 1,807 | 1,484 | 1,639 | 1,821 | 1,571 | 1,053 | 1,442 | 1,356 | 1,190 | 720 |
| Operating Profit % | 24.00% | 24.00% | 21.00% | 27.00% | 26.00% | 25.00% | 20.00% | 22.00% | 25.00% | 23.00% | 16.00% | 23.00% | 21.00% | 20.00% | 13.00% |
| Depreciation | 297 | 253 | 309 | 280 | 272 | 247 | 288 | 233 | 290 | 239 | 346 | 272 | 299 | 254 | 290 |
| Interest | 13 | 14 | 14 | 15 | 15 | 18 | 18 | 30 | 26 | 16 | 34 | 32 | 26 | 18 | 18 |
| Profit Before Tax | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 | 1,611 | 1,259 | 1,474 | 1,594 | 1,375 | 745 | 1,218 | 1,100 | 975 | 448 |
| Tax | 500 | 478 | 290 | 342 | 484 | 436 | 327 | 405 | 439 | 377 | 224 | 410 | 303 | 268 | 77 |
| Net Profit | 1,353 | 1,292 | 1,214 | 1,575 | 1,305 | 1,176 | 932 | 1,068 | 1,155 | 998 | 522 | 808 | 797 | 706 | 371 |
| EPS | 16.73 | 16.07 | 15.13 | 19.45 | 16.13 | 14.58 | 11.63 | 13.08 | 14.01 | 12.34 | 6.51 | 9.92 | 9.78 | 8.51 | 4.49 |
Cipla Cash Flow Screener - Liquidity Fundamentals
Screen CIPLA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 | 1,691 | 1,463 | 2,382 | 1,741 |
| Investing Activities | -3,682 | -2,983 | -2,376 | -1,858 | -2,374 | 114 | -1,688 | -834 | -1,304 | -4,533 |
| Financing Activities | -1,293 | -1,200 | -958 | -1,600 | -1,240 | -2,949 | -349 | -386 | -1,326 | 3,104 |
| Net Cash Flow | 30 | -49 | -97 | -132 | 141 | 234 | -345 | 243 | -248 | 312 |
Screen CIPLA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 29.20% | 29.19% | 29.21% | 33.47% | 30.91% | 30.92% | 29.19% | 33.55% |
| FII Holding | 26.28% | 25.25% | 24.55% | 25.83% | 27.81% | 28.80% | 26.65% | 0.00% |
| DII Holding | 28.15% | 29.26% | 30.25% | 24.42% | 24.95% | 24.16% | 27.71% | 22.10% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 14.13% | 14.10% | 13.82% | 14.20% | 14.24% | 14.16% | 14.29% | 14.85% |
| Other Holding | 2.23% | 2.20% | 2.16% | 2.08% | 2.09% | 1.95% | 2.15% | 29.50% |
| Shareholder Count | 543,420 | 549,655 | 534,587 | 436,154 | 463,569 | 470,234 | 525,114 | 475,293 |
Cipla Dividend Screener - Share Yield Analysis
Screen CIPLA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹16.00 | 1.06% |
| 2024-March | ₹13.00 | 0.90% |
| 2023-March | ₹8.50 | 0.57% |
| 2022-March | ₹5.00 | 0.56% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹4.00 | 0.49% |
| 2019-March | ₹3.00 | 0.71% |
| 2018-March | ₹3.00 | 0.57% |
| 2017-March | ₹2.00 | 0.37% |
Cipla Index Membership - Market Screener Classification
Screen CIPLA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Cipla Market Events Screener - Corporate Actions
Screen CIPLA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -0.11% |
| 2025-10-30 | 2025-10-30 | Quarterly Result Announcement | NA | 3.46% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -1.20% |
| 2025-07-16 | 2025-07-16 | Annual General Meeting | NA | -1.40% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 3.00 /share | 0.12% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 13.00 /share | 0.12% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 6.81% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -7.56% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -9.10% |
| 2024-08-20 | 2024-08-20 | Annual General Meeting | NA | 15.95% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 13.00 /share | 13.79% |
| 2023-07-21 | 2023-07-21 | Dividend | ₹ 8.50 /share | 11.89% |
| 2022-08-26 | 2022-08-26 | Annual General Meeting | NA | 7.37% |
| 2022-08-08 | 2022-08-10 | Dividend | ₹ 5.00 /share | 9.81% |
| 2021-08-09 | 2021-08-11 | Dividend | ₹ 5.00 /share | 1.56% |
Cipla Competitors Screener - Peer Comparison
Screen CIPLA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Cipla Company Announcements - News Screener
Screen CIPLA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-29 | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Friday 23Rd January 2026 Inter-Alia To Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31S | View |
| 2025-12-28 | Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-19 | Cipla Limited Has Entered Into Exclusive Supply And Marketing Agreement For PfizerS Brands | View |
| 2025-12-17 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-10 | Update On Launch Of Yurpeak® (Tirzepatide) In India For The Treatment Of Obesity And Type 2 Diabetes | View |
| 2025-12-10 | Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-03 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-30 | Outcome Of Board Meeting Dated 30Th October 2025 | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-10-30 | Board Meeting Outcome for Financial Results For Quarter And Half Year Ended 30Th September 2025 | View |
| 2025-10-30 | Financial Results For Quarter And Half Year Ended 30Th September 2025 | View |